Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2018. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 1192588019 | Betamethasone+salicylic acid 0.05/3% ointment (product) | en | Fully specified name | Inactive | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3692869013 | Betamethasone (as betamethasone dipropionate) 500 microgram/g and salicylic acid 30 mg/g cutaneous ointment | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3692870014 | Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | en | Synonym (core metadata concept) | Inactive | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3692871013 | Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 468563019 | Betamethasone+salicylic acid 0.05/3% ointment | en | Synonym (core metadata concept) | Inactive | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 721426011 | Betamethasone+salicylic acid 0.05/3% ointment (substance) | en | Fully specified name | Inactive | Only initial character case insensitive (core metadata concept) | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Betamethasone (as betamethasone dipropionate) 500 microgram/g and salicylic acid 30 mg/g cutaneous ointment | est un(e) (attribut) | Betamethasone and salicylic acid only product in cutaneous dose form | true | Inferred relationship | Some | ||
| Betamethasone (as betamethasone dipropionate) 500 microgram/g and salicylic acid 30 mg/g cutaneous ointment | Plays role | Antifungal therapeutic role (role) | true | Inferred relationship | Some | ||
| Betamethasone (as betamethasone dipropionate) 500 microgram/g and salicylic acid 30 mg/g cutaneous ointment | est un(e) (attribut) | Product containing betamethasone and salicylic acid (medicinal product) | false | Inferred relationship | Some | ||
| Betamethasone (as betamethasone dipropionate) 500 microgram/g and salicylic acid 30 mg/g cutaneous ointment | a pour principe actif (attribut) | Betamethasone | false | Inferred relationship | Some | ||
| Betamethasone (as betamethasone dipropionate) 500 microgram/g and salicylic acid 30 mg/g cutaneous ointment | a pour principe actif (attribut) | Adrenal hormone | false | Inferred relationship | Some | ||
| Betamethasone (as betamethasone dipropionate) 500 microgram/g and salicylic acid 30 mg/g cutaneous ointment | a pour principe actif (attribut) | Corticosterone | false | Inferred relationship | Some | ||
| Betamethasone (as betamethasone dipropionate) 500 microgram/g and salicylic acid 30 mg/g cutaneous ointment | a pour principe actif (attribut) | Adrenal hormone agent (substance) | false | Inferred relationship | Some | ||
| Betamethasone (as betamethasone dipropionate) 500 microgram/g and salicylic acid 30 mg/g cutaneous ointment | a pour principe actif (attribut) | Salicylic acid (substance) | false | Inferred relationship | Some | ||
| Betamethasone (as betamethasone dipropionate) 500 microgram/g and salicylic acid 30 mg/g cutaneous ointment | a pour principe actif (attribut) | Keratolytic agent (substance) | false | Inferred relationship | Some | ||
| Betamethasone (as betamethasone dipropionate) 500 microgram/g and salicylic acid 30 mg/g cutaneous ointment | a pour principe actif (attribut) | Glucocorticoid hormone | false | Inferred relationship | Some | ||
| Betamethasone (as betamethasone dipropionate) 500 microgram/g and salicylic acid 30 mg/g cutaneous ointment | a pour principe actif (attribut) | Topical agent (substance) | false | Inferred relationship | Some | ||
| Betamethasone (as betamethasone dipropionate) 500 microgram/g and salicylic acid 30 mg/g cutaneous ointment | a une forme pharmaceutique (attribut) | Cutaneous AND/OR transdermal dosage form | false | Inferred relationship | Some | ||
| Betamethasone (as betamethasone dipropionate) 500 microgram/g and salicylic acid 30 mg/g cutaneous ointment | a une forme pharmaceutique (attribut) | Ointment | false | Inferred relationship | Some | ||
| Betamethasone (as betamethasone dipropionate) 500 microgram/g and salicylic acid 30 mg/g cutaneous ointment | est un(e) (attribut) | Product containing betamethasone in topical dosage form (medicinal product form) | false | Inferred relationship | Some | ||
| Betamethasone (as betamethasone dipropionate) 500 microgram/g and salicylic acid 30 mg/g cutaneous ointment | est un(e) (attribut) | Product containing salicylic acid in topical dosage form (medicinal product form) | false | Inferred relationship | Some | ||
| Betamethasone (as betamethasone dipropionate) 500 microgram/g and salicylic acid 30 mg/g cutaneous ointment | a une forme pharmaceutique (attribut) | Cutaneous ointment | true | Inferred relationship | Some | ||
| Betamethasone (as betamethasone dipropionate) 500 microgram/g and salicylic acid 30 mg/g cutaneous ointment | Has concentration strength denominator value | un | false | Inferred relationship | Some | 1 | |
| Betamethasone (as betamethasone dipropionate) 500 microgram/g and salicylic acid 30 mg/g cutaneous ointment | Has concentration strength denominator value | un | false | Inferred relationship | Some | 2 | |
| Betamethasone (as betamethasone dipropionate) 500 microgram/g and salicylic acid 30 mg/g cutaneous ointment | Has concentration strength denominator unit | g | true | Inferred relationship | Some | 2 | |
| Betamethasone (as betamethasone dipropionate) 500 microgram/g and salicylic acid 30 mg/g cutaneous ointment | Has concentration strength denominator unit | g | true | Inferred relationship | Some | 1 | |
| Betamethasone (as betamethasone dipropionate) 500 microgram/g and salicylic acid 30 mg/g cutaneous ointment | Count of base of active ingredient | deux | false | Inferred relationship | Some | ||
| Betamethasone (as betamethasone dipropionate) 500 microgram/g and salicylic acid 30 mg/g cutaneous ointment | Has basis of strength substance (attribute) | Betamethasone | true | Inferred relationship | Some | 1 | |
| Betamethasone (as betamethasone dipropionate) 500 microgram/g and salicylic acid 30 mg/g cutaneous ointment | Has concentration strength numerator unit | milligram (qualifier value) | true | Inferred relationship | Some | 2 | |
| Betamethasone (as betamethasone dipropionate) 500 microgram/g and salicylic acid 30 mg/g cutaneous ointment | Has concentration strength numerator value (attribute) | 30 (qualifier value) | false | Inferred relationship | Some | 2 | |
| Betamethasone (as betamethasone dipropionate) 500 microgram/g and salicylic acid 30 mg/g cutaneous ointment | Has concentration strength numerator value (attribute) | 500 (qualifier value) | false | Inferred relationship | Some | 1 | |
| Betamethasone (as betamethasone dipropionate) 500 microgram/g and salicylic acid 30 mg/g cutaneous ointment | Has basis of strength substance (attribute) | Salicylic acid (substance) | true | Inferred relationship | Some | 2 | |
| Betamethasone (as betamethasone dipropionate) 500 microgram/g and salicylic acid 30 mg/g cutaneous ointment | Has precise active ingredient | Salicylic acid (substance) | true | Inferred relationship | Some | 2 | |
| Betamethasone (as betamethasone dipropionate) 500 microgram/g and salicylic acid 30 mg/g cutaneous ointment | Has concentration strength numerator unit | microgram (qualifier value) | true | Inferred relationship | Some | 1 | |
| Betamethasone (as betamethasone dipropionate) 500 microgram/g and salicylic acid 30 mg/g cutaneous ointment | Has precise active ingredient | Betamethasone dipropionate | true | Inferred relationship | Some | 1 |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets
FHIR